NIH panel report of 'no flaws' in FIAU trial at variance with FDA report, new probe planned.
Marwick
C
C
D000998:Antiviral Agents / Q000009:adverse effects*; D001086:Arabinofuranosyluracil / Q000009:adverse effects / Q000031:analogs & derivatives*; D002423:Cause of Death; D056486:Chemical and Drug Induced Liver Injury; D002986:Clinical Trials as Topic; D006509:Hepatitis B / Q000188:drug therapy; D006521:Hepatitis, Chronic / Q000188:drug therapy; D006801:Humans; D008107:Liver Diseases / Q000401:mortality; D009316:National Institutes of Health (U.S.); D015871:Scientific Misconduct; D014481:United States; D014486:United States Food and Drug Administration
D000998:Antiviral Agents; D001086:Arabinofuranosyluracil; C043457:fialuridine